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Background: Increased intracellular protein O-GlcNAc modification may contribute to delayed wound healing in
diabetes.
Results: Hyperglycemia increases intracellular protein O-GlcNAc modification and delays wound healing in keratinocytes.
Targeted knockdown of OGT altered rates of wound closure.
Conclusion: OGT knockdown accelerates wound healing under both normal and hyperglycemic culture conditions.
Significance: OGT may represent a novel druggable target for promoting healing of diabetic wounds.
Non-healing wounds are a significant source of morbidity.
This is particularly true for diabetic patients, who tend to
develop chronic skin wounds. O-GlcNAc modification of serine
and threonine residues is a common regulatory post-transla-
tional modification analogous to protein phosphorylation;
increased intracellular protein O-GlcNAc modification has
been observed in diabetic and hyperglycemic states. Two intra-
cellular enzymes, UDP-N-acetylglucosamine-polypeptide -N-
acetylglucosaminyl transferase (OGT) and O-GlcNAc-selective
N-acetyl--D-glucosaminidase (OGA), mediate addition and
removal, respectively, of N-acetylglucosamine (GlcNAc) from
intracellular protein substrates. Alterations in O-GlcNAc mod-
ification of intracellular proteins is linked to diabetes, and the
increased levels of protein O-GlcNAc modification observed in
diabetic tissues may in part explain some of the observed under-
lying pathophysiology that contributes to delayed wound heal-
ing. We have previously shown that increasing protein
O-GlcNAc modification by overexpression of OGT in murine
keratinocytes results in elevated protein O-GlcNAc modifica-
tion and a hyperadhesive phenotype. This study was undertaken
to explore the hypothesis that increased O-GlcNAc modifica-
tion of cellular proteins in diabetic skin could contribute to the
delayed wound healing observed in patients with diabetic skin
ulcers. In the present study, we show that human keratinocytes
cultured under hyperglycemic conditions display increased lev-
els of O-GlcNAc modification as well as a delay in the rate of
wound closure in vitro. We further show that specific knock-
down of OGT by RNA interference (RNAi) reverses this effect,
thereby opening up the opportunity for OGT-targeted therapies
to promote wound healing in diabetic patients.
Non-healing wounds are a significant source of morbidity
affecting 6.5 million patients in the United States and costing
approximately $25 billion annually to treat (1). Patients with
diabetes are at increased risk for developing non-healing
wounds. A variety of factors likely contribute to the predispo-
sition of diabetic patients to develop non-healing wounds
including neuropathy, vasculopathy, as well as the underlying
endocrine dysfunction that results in elevated glucose levels.
Like phosphorylation, intracellular protein O-GlcNAc modifi-
cation is a common, dynamic post-translational modification that
regulates many intracellular proteins including enzymes, tran-
scription factors, structural, and cell adhesion proteins. N-Acetyl-
glucosamine (GlcNAc) modification of serine and threonine is cat-
alyzed by the enzyme UDP-N-acetylglucosamine-polypeptide
-N-acetylglucosaminyl transferase (O-GlcNAc transferase,
OGT),2 whereas GlcNAc is removed by O-GlcNAc-selective
N-acetyl--D-glucosaminidase (GlcNAcase, OGA) (reviewed
in Ref. 2).
Hyperglycemia, excess glucose, feeds into the glucosamine
pathway to provide excess UDP-GlcNAc for OGT to modify
intracellular proteins (3). Excess glucose is converted to glucos-
amine, which is ultimately converted to UDP-N-acetylglucos-
amine (UDP-GlcNAc), the donor substrate for OGT modifica-
tion of intracellular proteins. Consequently, hyperglycemia is
associated with increased O-GlcNAc modification of a variety
of proteins (3–7). The increased O-GlcNAc modification of
intracellular proteins observed in hyperglycemic states includ-
ing diabetes is thought to contribute to some of the pathology
associated with diabetes. For example, (i) pancreatic -cells
have high levels of OGT and are sensitive to alterations in intra-
cellular O-GlcNAc modification and (ii) overexpression of
OGT in muscle and adipose tissue causes diabetes in transgenic
mouse models (8). Increased O-GlcNAc modification of intra-
cellular proteins is observed in diabetic tissue, including human
diabetic tissue (9) and hyperglycemic animal models (4). Fur-
ther support for a pathologic role for intracellular O-GlcNAc
modification in diabetes comes from studies demonstrating a
genetic association of diabetes and mutations causing increased
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intracellular protein O-GlcNAc modification; a mutation that
results in early termination in the gene encoding OGA has been
associated with a genetic predisposition to adult onset type II
diabetes in a Mexican American population (10). OGA removes
O-GlcNAc from intracellular proteins, and the identified OGA
mutations result in increased levels of protein O-GlcNAc
modification.
During wound healing, keratinocytes at the wound margin
must down-regulate adhesion to adjacent cells to permit move-
ment away from the edge and into the wound (11). Previous
data from our group demonstrated that increased O-GlcNAc
modification stabilizes cell-cell adhesion in part by increasing
the post-translational stability of desmosome components
including plakoglobin (12). By increasing cell-cell adhesion, we
hypothesize that increased intracellular protein O-GlcNAc
modification retards wound healing. This study was under-
taken to explore the hypothesis that increased O-GlcNAc mod-
ification of cellular proteins in diabetic skin could contribute to
the delayed wound healing observed in patients with chronic
diabetic skin ulcers. In the present study we modeled hypergly-
cemia by culturing human keratinocytes in elevated glucose.
Under hyperglycemic conditions, we observed (i) increased lev-
els of O-GlcNAc modification of keratinocyte proteins and
importantly (ii) delays in wound closure. Hyperglycemia-in-
duced delays in wound closure were reversed by shRNA and
siRNA knockdown of OGT, the gene responsible for adding the
GlcNAc moiety to proteins. These observations suggest that
targeting OGT may be beneficial for treating non-healing dia-
betic wounds.
EXPERIMENTAL PROCEDURES
Materials—Cell culture media were obtained from Invitrogen.
shRNA plasmids were purchased from Open Biosystems (Thermo
Fisher Scientific) and packaged into inactivated lentivirus particles
at The University of North Carolina at Chapel Hill Lenti-shRNA
core facility. The sequences for the mature sense strands in
the hairpins were: shOGT (TRCN0000035064), 5-GCCCTA-
AGTTTGAGTCCAAAT-3, and shOGA (TRCN0000134040),
5-CCAGAAACTTTCCTTGCTAAT-3. The RNAi Consortium
(TRC) lentiviral enhanced GFP shRNA was used as a positive
control for transduction (Open Biosystems catalog number
RHS4459). Mouse monoclonal O-GlcNAc-specific antibodies
(clone RL2) were from Thermo Scientific. Rabbit monoclonal
antibodies to GAPDH were from Cell Signaling (Danvers, MA).
Mouse monoclonal antibodies to -actin were from Sigma. Rabbit
polyclonal OGT antibodies were from Abcam (Cambridge, MA).
Mouse and rabbit anti-sheep horseradish peroxidase-conjugated
secondary antibodies were from GE Healthcare. Control siRNA
(sense strand: GCAGUUAUAAUGACUAGAU) and OGT
siRNA (sense strand: GCACAAUCCUGAUAAAUUU) with
3UU overhangs were purchased from Sigma-Aldrich.
Cell Culture and Scratch Wounding—Untransfected and
shRNA-transfected HaCaT cells were cultured in normal or
high glucose Dulbecco’s modified Eagle’s medium (DMEM)
(5.5 or 25 mM glucose, respectively) (13), 1% fetal bovine serum
(FBS), 1,000 units penicillin/ml, 100 g streptomycin/ml.
Media were supplemented with the amounts of glucose or
inhibitor specified in the figure legends. shRNA-transfected
cells were selected using 1 g of puromycin/ml of medium.
Puromycin-containing media were replaced 6 h prior to
scratching. Cells were grown for 60 h (until confluent) before
scratch assays were performed. Scratch wounds were per-
formed by making a linear scratch across monolayers of conflu-
ent cells in 24-well culture plates followed by one wash with 1
PBS and the addition of fresh culture medium. Pictures were
taken on a Nikon TE2000-U spinning disk microscope using a
10 magnification immediately after scratching and incubated
at 37 °C for the amount of time stated in the figure legends
before another set of pictures was taken. Wounds were subse-
quently analyzed using the TScratch software package (14).
Only wounds of the same initial wound-size were evaluated and
compared.
Statistical Analyses—Error bars reflect the S.E. Student’s t
tests were performed as two-sided tests with unequal variance
as described in the TScratch software manual.
Stable Transduction of Keratinocytes with shRNAs—HaCaT
cells were cultured in DMEM, 10% FBS to 50 – 60% confluency
and incubated with 10 g/ml Polybrene and shRNA (shGFP,
shOGT, or shOGA) using a multiplicity of infection of two, 5 h
after which the medium was changed to fresh DMEM. The
following day, medium containing 1 g/ml puromycin was
added to the cells to select for successfully transduced cells. Cell
cultures were passaged 6 – 8 times under puromycin selection
before they were used for experiments.
Quantification of Immunoblot Signals—Samples were
equally loaded on and separated by SDS-PAGE as described
previously (12). Immunoblotting was performed according to
established protocols and developed by enhanced chemilumi-
nescence (ECL) reaction (Amersham Biosciences). Protein
bands from immunoblots were quantified using the GeneSnap
software (SynGENE, Frederick, MD). For RL2 staining, the
three most prominent bands were analyzed using GeneSnap
software.
siRNA Transfection of Keratinocytes—siRNA against OGT
(3-GCACAAUCCUGAUAAAUUU-5) and a scrambled con-
trol siRNA (3-GCAGUUAUAAUGACUAGAU-5) were syn-
thesized with 3-UU overhands and were diluted to 20 mM in
water (working stock), and each well in a 24-well plate with 40%
confluent keratinocytes was transfected using Oligofectamine
(Invitrogen) according to the protocol. Briefly, 3 l of Oligo-
fectamine (Invitrogen) was diluted in 12 l of Opti-MEM I
(Invitrogen) and incubated for 8 min. In the meantime 3 l of
siRNA was mixed with 50 l of Opti-MEM I, and this was added
to the Oligofectamine dilution and left to form complexes for
20 min. 32 l of Opti-MEM was then added to the mix and
added to the cells (in 500 l of high glucose DMEM). After 48 h
the medium was changed to high glucose DMEM, and at 60 h
the cells were used for scratch assay. Pictures were taken at the
time points described in the figure legends.
RESULTS
Hyperglycemic Conditions Result in Elevated Protein
O-GlcNAc Levels in Human Keratinocytes—To investigate
whether increased levels of O-GlcNAc modification in diabetic
skin may be linked to elevated tissue glucose levels, these con-
ditions were mimicked in cell culture by growing human kera-
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tinocytes (HaCaT) for 48 h with various glucose concentrations
(Fig. 1). Immunoblot of cell lysates shows that increased levels
of glucose indeed resulted in more O-GlcNAc modification in
keratinocyte lysates, as detected by the O-GlcNAc-specific
antibody RL2 (Fig. 1, A and B). This dose-dependent increase in
O-GlcNAcylation emphasizes the link between increased glu-
cose concentrations and intracellular protein O-GlcNAc mod-
ification in keratinocytes.
Human Keratinocytes Exhibit Delayed Wound Healing under
Hyperglycemic Conditions—We then utilized the in vitro kera-
tinocyte scratch assay model of wound healing to test the
hypothesis that hyperglycemic conditions decrease the rate of
wound closure (Fig. 1, C and D). The assay was performed by
preincubating HaCaT cells with different amounts of glucose
for 48 h, after which a wound was introduced in the confluent
layer of cells. Elevated levels of glucose in the culture media
decreased the rate of wound closure in a dose-dependent man-
ner (Fig. 1, C and D).
Gene Knockdown of Key Enzymes for the O-GlcNAc Pathway
by RNA Interference Affects the Rate of Wound Closure in
Human Keratinocyte Culture—The apparent link between
delayed wound closure and elevated levels of O-GlcNAc mod-
ification in HaCaT cells led us to further investigate the role of
the enzymes responsible for the addition and removal of
O-GlcNAc protein modification (OGT and OGA, respectively)
in more detail. To do this, we stably transduced HaCaT cells
with shRNAs against either enzyme and analyzed cell lysates by
immunoblot analysis (Fig. 2, A and B). Immunoblot analysis of
the cell lysates confirmed the impact of RNAi on O-GlcNAc
levels, with shOGT displaying significantly reduced levels of
O-GlcNAc modification. The shOGA transduced cells dis-
played levels of O-GlcNAc modification similar to both the
untransduced cells and the shGFP controls (Fig. 2B). Scratch-
wounding assays of shRNA-transduced cells show that knock-
ing down OGT significantly increases the rate of wound closure
(Fig. 2, C and D). shOGA transduced cells were not significantly
different from shGFP transduced controls despite evidence
that targeting OGA with shRNA reduced total OGA protein
levels (data not shown). Collectively, these data strongly suggest
that decreasing the amount of O-GlcNAc (via shOGT) acceler-
ates wound healing, providing additional support for the rela-
tionship between O-GlcNAc protein modification and wound
healing.
siRNA Knockdown of OGT Decreases Keratinocyte O-GlcNAc
Modification and Accelerates Wound Closure in Hyperglycemic
Conditions—To investigate the therapeutic potential of siRNA
knockdown to down-regulate OGT expression, we tested
OGT-specific siRNAs as a means to knock down OGT and
accelerate wound healing in the keratinocyte scratch model
(Fig. 3). A 19-mer siRNA directed against the OGT mRNA
sequence was synthesized, and HaCaT cells were transfected
with the OGT-specific silencing RNA as well as a control siRNA
with a scrambled sequence. 2 days after transfection, cell lysates
were probed for RL2 and OGT immunoreactivity (Fig. 3, A and
B). The results show that siRNA against OGT results in a
marked knockdown in both OGT levels and RL2 immunoreac-
tivity as quantified from immunoblots.
Next, siRNA-transfected cells were tested in a scratch-
wounding assay to examine the effect of this form of OGT RNAi
on wound closure in vitro. Fig. 3C shows that wound healing at
the 26-h time point is significantly more progressed with OGT
siRNA as compared with both control siRNA and untreated
cells (Fig. 3D). These results further support the hypothesis that
the level of intracellular O-GlcNAc modification in human
keratinocytes is linked to wound closure rate and that this may
be manipulated using OGT knockdown.
DISCUSSION
Increasing evidence from the literature suggests that altera-
tions in the hexosamine pathway play a key role in the patho-
physiology of diabetes. For example, overexpression of OGT in
mice results in a diabetic phenotype (8), and increased levels of
O-GlcNAc modification have been observed in cells and tissue
from type 2 diabetes patients relative to healthy controls (9, 15).
Previously, we had reported that overexpression of OGT in
keratinocytes (i) increases GlcNAc modification of cellular pro-
teins and (ii) markedly enhances cell-cell adhesion (12). Con-
sistent with these observations, we observed a dose-dependent
increase in protein O-GlcNAc modification in human keratino-
cyte cultures grown in increasing concentrations of glucose.
Furthermore, increasing concentrations of glucose and O-
GlcNAc protein modification were associated with delayed
wound closure in a dose-dependent fashion. Significantly,
silencing OGT activity with either OGT-specific shRNA or
OGT-specific siRNA decreases GlcNAc modification of kerati-
nocyte proteins and promotes wound healing in a scratch
model assay, even in the presence of elevated glucose concen-
FIGURE 1. Hyperglycemia increases O-GlcNAc modification and retards
wound healing in human keratinocytes. HaCaT cells were cultured in
media supplemented with glucose to the final concentrations indicated. A,
representative immunoblot (IB) of cell lysates separated by SDS-PAGE and
immunoprobed with antibodies to (i) RL2, which recognizes the O-GlcNAc
modification, and (ii) GAPDH as a loading control. B, the RL2 signal was quan-
tified relative to the GAPDH loading control (n  3). C and D, scratch assays.
Human keratinocyte monolayers were incubated in DMEM with the indicated
glucose concentrations. Cells were scratched with a pipette tip, and micro-
graphs were made at 0 and 16 h. Wound sizes were then measured using
image analysis software. Representative micrographs are shown in C and
quantified in D. n  11 for all conditions. Error bars reflect the S.E. * indicates p
value 0.07 and ** indicates p value  0.0005 as compared with normal
glucose levels (5.5 mM). The p value between 25 and 100 mM is 0.01.
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trations. Collectively, these observations suggest that increased
intracellular O-GlcNAc modification, mediated by the enzyme
OGT, likely contributes to delayed wound healing in non-heal-
ing diabetic skin wounds.
The effects of increased OGT activity on promoting cell
adhesion and delaying wound healing may in part be due to
regulation of keratinocyte cell adhesion components, including
desmosomes, adherens junctions, and cytoskeletal elements as
we have previously reported (12). In this context, we previously
showed that plakoglobin, a component of both adherens junc-
tion and desmosome cell-cell adhesion complexes, is post-
translationally stabilized by increased O-GlcNAc modification
in OGT-overexpressing keratinocytes. This increased plako-
globin protein level drove formation of desmosomes and pla-
koglobin-based adherens junctions and markedly enhanced
cell-cell adhesion (12). These observations indicate that in kera-
tinocytes, O-GlcNAc modification functions in part to regulate
the post-translational stability of plakoglobin, and significantly,
to regulate keratinocyte cell-cell adhesion. During wound heal-
ing, keratinocytes migrate into the wound to promote re-epi-
thelialization. Keratinocytes at the wound margin must
down-regulate adhesion to adjacent cells at the trailing mar-
gin to permit movement away from the edge and into the
wound. By increasing cell-cell adhesion, we suggest that
increased intracellular protein O-GlcNAc modification
retards wound healing, whereas down-regulation of intracel-
lular protein O-GlcNAc modification promotes wound
healing.
It is worth noting that O-GlcNAc is a ubiquitous intracellular
modification. In addition to modifying cell adhesion and struc-
tural proteins, transcription factors and regulatory enzymes are
also modified by OGT-catalyzed addition of GlcNAc to serine
and threonine residues. Thus, the effects of OGT activity are
likely to be pleiotropic. In addition to its effects on adhesion,
altering levels of intracellular protein O-GlcNAc modification
may also impact cell proliferation and chemotaxis, and it may
be the combination of these effects that contributes to the
observed delayed wound healing.
Diabetic wounds represent a significant health care burden.
The incidence and social and financial cost of treating these
wounds are likely to increase as the incidence of diabetes rises
due to the obesity epidemic and aging populations. We have
demonstrated that decreasing the global level of O-GlcNAc
modification through knockdown of OGT using RNAi acceler-
ates wound healing in a hyperglycemic keratinocyte culture
model. Collectively, these data show that locally targeting OGT
FIGURE 2. OGT knockdown using shRNA accelerates wound healing. HaCaT cells were stably transduced with shRNA targeting OGT, OGA, and GFP (control)
and grown to confluency. A, OGT knockdown decreases protein O-GlcNAcylation. Cell lysates were analyzed by immunoblot (IB) with antibodies to (i) O-GlcNAc
(RL2), (ii) OGT, and (iii) actin (loading control). B, RL2 reactivity was quantified as compared with actin. Untr, untreated cells. C and D, OGT knockdown promotes
wound healing in hyperglycemic cultures. Transduced cells were grown to confluency in growth medium with 25 mM glucose and scratched to introduce
wounds. Representative micrographs obtained at 0 and 12 h are shown in panel C, whereas the quantification of open wound areas is shown in panel D. In the
scratch-wounding assay, n  18 for untreated cells, n  10 for shGFP, n  8 for shOGT, and n  14 for shOGA. Error bars reflect the S.E. * indicates p value  0.05.
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may prove an effective approach to promote healing in diabetic
ulcers. As it has previously been demonstrated that the
impaired barrier function in wounds allows for transfection
with oligonucleotides (16), we suggest that topical administra-
tion of siRNAs or antisense oligodeoxynucleotides against
OGT may be an effective treatment to promote healing of dia-
betic skin wounds.
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